Summer may be ending, but enforcement from the Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) is just heating up. After months of silence (see here for our discussion of OPDP’s first enforcement letter of 2024 five months ago), OPDP issued back-to-back Untitled Letters in July and August bringing the total... READ MORE
Summer Is Heating Up with Two New OPDP Untitled Letters
Posted on August 22, 2024 in Health Law News
Published by: Hall Render
